| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.56% | 82.78% | 83.01% | 81.96% | 83.26% | 84.16% | 85.60% | 89.87% | 89.03% | 95.89% | 89.21% | 89.29% |
| Operating Margin | 15.26% | 16.87% | 11.55% | -9.32% | -1.95% | -18.29% | -7.07% | -1.09% | 14.39% | 8.32% | 13.01% | 6.01% |
| EBITDA Margin | 18.82% | 18.60% | 12.61% | -8.07% | -0.26% | -15.96% | -4.88% | 0.55% | 15.67% | 9.82% | 13.97% | 7.02% |
| Net Margin | 11.60% | 12.16% | 18.11% | -11.27% | -3.98% | -19.85% | -8.55% | -8.35% | 20.16% | 5.40% | 15.72% | 5.26% |
| Current Ratio | 4.32 | 4.21 | 3.57 | 3.08 | 3.51 | 2.71 | 1.83 | 1.03 | 1.06 | 2.49 | 3.60 | 4.66 |
| Quick Ratio | 3.92 | 3.69 | 3.11 | 2.78 | 3.24 | 2.54 | 1.70 | 0.81 | 0.86 | 2.14 | 3.32 | 4.38 |
| Debt / Equity | 0.07 | 0.10 | 0.34 | -2.70 | 586.91 | -317.98 | 1.91 | 0.00 | — | — | — | — |
| ROE | 18.94% | 21.97% | 40.80% | 167.87% | -12542.68% | 32856.00% | -74.36% | -60.37% | 87.71% | 9.00% | 27.27% | 6.96% |
| ROA | 14.18% | 16.07% | 24.36% | -17.61% | -5.47% | -24.39% | -15.30% | -24.40% | 53.38% | 6.20% | 21.67% | 5.69% |
| Asset Turnover | 1.22 | 1.32 | 1.34 | 1.56 | 1.38 | 1.23 | 1.79 | 2.92 | 2.65 | 1.15 | 1.38 | 1.08 |
| Book Value / Share | 1.71 | 1.30 | 0.98 | -0.16 | 0.00 | -0.00 | 0.32 | 0.47 | 0.64 | 1.18 | 0.95 | 0.79 |
MiMedx Group, Inc. is a leading biopharmaceutical company specializing in regenerative medicine. The company's primary focus is on the development and commercialization of innovative bioimplants derived from human placental tissues. MiMedx's products are designed to enhance healing by leveraging the innate properties of placental tissue to treat a variety of conditions, including chronic and hard-to-heal wounds, surgical sites, and musculoskeletal injuries. These advanced solutions cater to the needs of healthcare providers across the wound care, ophthalmology, and orthopedics sectors. By addressing critical gaps in the treatment of complex medical conditions, MiMedx plays a significant role in advancing regenerative medicine technologies. The company's commitment to research and development in tissue engineering continues to drive its influence in the healthcare market, offering solutions that not only improve patient outcomes but also reduce overall treatment costs. Through its cutting-edge products and continuous innovation, MiMedx Group, Inc. contributes meaningfully to the evolving landscape of biopharmaceuticals.